Evidence map›Paper›PMID 39777144›Full record

ArticleFrontiers in microbiology2024

Highly diverse endophytic fungi from Serra do Amolar-Pantanal (Brazil) producing bioactive secondary metabolites against phytopathogens.

Bárbara Fanaya Mayrhofer, Jucélia Iantas, Sandriele Aparecida Noriler, Larissa V Ponomareva, Jon S Thorson, Jürgen Rohr, Khaled A Shaaban, Chirlei Glienke

Abstract read
In one paragraph

Article in Frontiers in microbiology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Bárbara Fanaya MayrhoferPostgraduate Program in Microbiology, Department of Pathology, Federal University of Paraná (UFPR), Centro Politécnico, Curitiba, Paraná, Brazil.
Jucélia IantasPostgraduate Program in Microbiology, Department of Pathology, Federal University of Paraná (UFPR), Centro Politécnico, Curitiba, Paraná, Brazil.
Sandriele Aparecida NorilerPostgraduate Program in Microbiology, Department of Pathology, Federal University of Paraná (UFPR), Centro Politécnico, Curitiba, Paraná, Brazil.
Larissa V PonomarevaCenter for Pharmaceutical Research and Innovation, College of Pharmacy, University of Kentucky, Lexington, KY, United States.
Jon S ThorsonCenter for Pharmaceutical Research and Innovation, College of Pharmacy, University of Kentucky, Lexington, KY, United States.
Jürgen RohrDepartment of Pharmaceutical Sciences, College of Pharmacy, University of Kentucky, Lexington, KY, United States.
Khaled A ShaabanCenter for Pharmaceutical Research and Innovation, College of Pharmacy, University of Kentucky, Lexington, KY, United States.
Chirlei GlienkePostgraduate Program in Microbiology, Department of Pathology, Federal University of Paraná (UFPR), Centro Politécnico, Curitiba, Paraná, Brazil.

Funding

Kentucky Center for Clinical and Translational ScienceUL1TR001998 · NCATS · UNIVERSITY OF KENTUCKY · PI HARTMANN, KATHERINE E, KERN, PHILIP A · 2016 to 2025
$34.2M
Understanding the role of anti-apolipoprotein A-I antibodies in atherosclerotic cardiovascular diseaseP20GM130456 · NIGMS · UNIVERSITY OF KENTUCKY · PI M. Ashfaqul Alam · 2020 to 2026
$18.7M
Kentucky Center for Clinical and Translational ScienceUL1TR000117 · NCATS · UNIVERSITY OF KENTUCKY · PI KERN, PHILIP A · 2012 to 2015
$13.3M
In Vitro Glycorandomization of Natural ProductsR37AI052218 · NIAID · UNIVERSITY OF KENTUCKY · PI THORSON, JON SCOTT · 2012 to 2021
$4.0M
Mechanistic and pharmacologic studies of selective mithramycin analogues targeting EWS-FLI1 in Ewing sarcomaR01CA243529 · NCI · UNIVERSITY OF KENTUCKY · PI LEGGAS, MARKOS, ROHR, JURGEN T · 2020 to 2024
$3.0M
NCATS NIH HHS UL1 TR000117NCATS NIH HHS UL1 TR001998NCI NIH HHS R01 CA243529NIAID NIH HHS R37 AI052218NIGMS NIH HHS P20 GM130456
6 · The paper itself

Abstract

Introduction: The exploration of new bioactive compounds for agricultural applications is critical for sustainable development. Endophytic fungi, particularly those from underexplored biomes in Brazil, represent a promising source of natural compounds. This study focused on isolation and bioprospecting endophytic fungi from the medicinal plant Methods and results: Leaves and petioles were collected from 18 V. divergens specimens, from which 293 endophytes were isolated and grouped by morphological characteristics into 91 phenotypes. One representative of each phenotype was selected for secondary metabolite extraction and taxonomic identification. Fungi belonging to 27 families and 32 different genera were identified, with Discussion: Finally, a very important contribution of this study was the

Indexed as

Diaporthenatural productsPantanalsecondary metabolitesSerra do AmolarVochysia divergensXylaria

Identifiers

PMID39777144
PMCPMC11703833

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.